如何借力中国优势加速全球化进程？｜CHIC

·in 6 hours发布

The 12th Annual China Healthcare Investment Conference (CHIC) will be held on March 23–24, 2026 at The Ritz-Carlton Shanghai Pudong Hotel.

• What is China's primary strength in the global biotechnology sector currently? And what makes it significant?

• Is China producing novel, pioneering innovations that attract international interest, or primarily building on existing developments?

• How did local elements significantly reduce durations or mitigate risks in a cross-border initiative?

• Regarding Createrna/InnaRX's framework—conducting rapid, cost-effective proof-of-concept locally, then expanding through a U.S. entity. This differs from common startup approaches by handling more extensive work internally. What drives this choice?

• From an academic perspective, can china's research findings be effectively scaled for commercial application, or do barriers remain in bridging discovery to practical use?

• Which areas show the most promising original intellectual property from academia at present, and how rapidly is it advancing to international partnerships or progression? What about partnerships between academia and industry?

• What is Marina’s activities, and what insights does its founder have on advancing highly innovative treatments?

• How does a major international pharmaceutical firm like Novo Nordisk engage with China's innovation landscape?…

The panel discussion themed “How to Leverage China's Advantages to Accelerate Global Development” will address the above questions.

The panel will be moderated by Yuan Yuan, Head of Platform Development, China, NEXTBio Capital.

Panelists:

• Bai Lu, Professor, Fudan University

• Jun Bao, Founder, Apuri BioVenture

• Jenny Yang, Head of External Innovation Asia Pacific, Novo Nordisk

• Wilson Wang, Head of Corporate Development, Createrna

• Jeffrey Su, CEO, Marina Biotherapeutics

• Michael Wen, Co-President, Tigermed

Agenda